Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Abroad (travel likely)RecruitingPHASE3

Conditions

Breast Cancer · Locoregional Recurrence · Abemaciclib · Endocrine Therapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Contact: Study coordinator (Yukinori Ozaki, MD. PhD.) · yukinori.ozaki@jfcr.or.jp · +81335200111

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

HR+/HER2- Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Anchorage, United States

Study of AVZO-021 in Patients With Advanced Solid Tumors

Advanced Solid Tumor · HR+/HER2- Breast Cancer · HR+, HER2-, Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

New Haven, United States · Sarasota, United States

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Breast Cancer · Hormone Receptor-positive Breast Cancer · Hormone Therapy

Abroad (travel likely)RecruitingPHASE2

Taipei, Taiwan · Taipei, Taiwan

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Bengbu, China · Fuyang, China